Business Description
Corona Remedies Ltd
ISIN : INE02ZQ01018
Total Employee Number:
4,573Compare
Compare
Traded in other countries / regions
CORONA.India IPO Date
2025-12-15Description
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.01 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | 0.81 | |||||
Interest Coverage | 42.1 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 19.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.6 | |||||
3-Year EBITDA Growth Rate | 28.5 | |||||
3-Year EPS without NRI Growth Rate | 33.1 | |||||
3-Year FCF Growth Rate | 91 | |||||
3-Year Book Growth Rate | 22.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 26.23 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 16.21 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.36 | |||||
9-Day RSI | 60.19 | |||||
14-Day RSI | 61.88 | |||||
3-1 Month Momentum % | 13.94 | |||||
6-1 Month Momentum % | 33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.96 | |||||
Quick Ratio | 0.62 | |||||
Cash Ratio | 0.01 | |||||
Days Inventory | 236.36 | |||||
Days Sales Outstanding | 48.43 | |||||
Days Payable | 259.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.48 | |||||
Forward Dividend Yield % | 0.48 | |||||
5-Year Yield-on-Cost % | 0.47 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 81.54 | |||||
Operating Margin % | 17.9 | |||||
Net Margin % | 12.75 | |||||
EBITDA Margin % | 19.56 | |||||
FCF Margin % | 1.21 | |||||
OCF Margin % | 2.43 | |||||
ROE % | 20.32 | |||||
ROA % | 12.66 | |||||
ROIC % | 16.65 | |||||
3-Year ROIIC % | 19.91 | |||||
ROC (Joel Greenblatt) % | 31.32 | |||||
ROCE % | 23.67 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 97.42 | |||||
Forward PE Ratio | 50.27 | |||||
PE Ratio without NRI | 87.89 | |||||
PS Ratio | 12.41 | |||||
PB Ratio | 17.32 | |||||
Price-to-Tangible-Book | 26.52 | |||||
Price-to-Free-Cash-Flow | 1025.77 | |||||
Price-to-Operating-Cash-Flow | 509.92 | |||||
EV-to-EBIT | 74.25 | |||||
EV-to-EBITDA | 63.8 | |||||
EV-to-Revenue | 12.47 | |||||
EV-to-FCF | 1037.68 | |||||
Price-to-Graham-Number | 9.2 | |||||
Earnings Yield (Greenblatt) % | 1.36 | |||||
FCF Yield % | 0.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Corona Remedies Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 10,417.95 | ||
| EPS (TTM) (₹) | 21.713 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 61.88 | ||
| 14-Day ATR (₹) | 67.172875 | ||
| 20-Day SMA (₹) | 2055.83 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (₹) | 1336.6 - 2145.9 | ||
| Shares Outstanding (Mil) | 61.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Corona Remedies Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Corona Remedies Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 10.000000 Cash Dividend | 2026-06-19 | 1,836.00 (+0.88%) |
Show
Entries
Corona Remedies Ltd Frequently Asked Questions
What is Corona Remedies Ltd(NSE:CORONA)'s stock price today?
The current price of NSE:CORONA is ₹2098.80. The 52 week high of NSE:CORONA is ₹2145.90 and 52 week low is ₹1336.60.
When is next earnings date of Corona Remedies Ltd(NSE:CORONA)?
The next earnings date of Corona Remedies Ltd(NSE:CORONA) is .
Does Corona Remedies Ltd(NSE:CORONA) pay dividends? If so, how much?
The Dividend Yield %  of Corona Remedies Ltd(NSE:CORONA) is 0.48% (As of Today), Highest Dividend Payout Ratio of Corona Remedies Ltd(NSE:CORONA) was 0. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Corona Remedies Ltd(NSE:CORONA) is 0.48%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Corona Remedies Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers